½ÃÀ庸°í¼­
»óǰÄÚµå
1454246

¼¼°èÀÇ ±â°üÁö È®ÀåÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº°.

Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography .

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀåÀº 2023³â¿¡´Â 228¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 304¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2023 2023/2024³â ½ÃÀå ±Ô¸ð 228¾ï 5,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019³â-2023³â ¿¹Ãø ±â°£ 2024-2031
¿¹Ãø ±â°£ 2023/2024-2030/2031 º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR): 3.60% 2030³â/2031³â °¡Ä¡ ¿¹Ãø 304¾ï 4,000¸¸ ´Þ·¯
±×¸² 1. ±â°üÁö È®ÀåÁ¦ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°(2023³â)
Global Bronchodilators Market-IMG1

±â°üÁö È®ÀåÁ¦´Â Æó±âµµ¸¦ ³ÐÈ÷°í È£ÈíÀ» ÆíÇϰÔÇÏ´Â ¾àÀÔ´Ï´Ù. ±â°üÁö È®ÀåÁ¦´Â ±â°üÁö¸¦ µÑ·¯½Î°í ÀÖ´Â ÆòȰ±ÙÀ» ÀÌ¿Ï,È®Àå½ÃÅ´À¸·Î½á ÀÛ¿ëÇÏ¿© õ¸í, ±âħ, ¼û°¡»Ý, ±âŸ õ½ÄÀ̳ª ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD) µîÀÇ È£Èí±â Áúȯ¿¡ µû¸¥ Áõ»óÀ» °æ°¨ÇÕ´Ï´Ù. ±â°üÁö È®ÀåÁ¦´Â °©ÀÛ½º·± ¼û°áÀÇ ¹ßÀÛÀ» ´Ü±âÀûÀ¸·Î ¿ÏÈ­Çϱâ À§ÇØ »ç¿ëµÇ´Â ´Ü½Ã°£ ÀÛ¿ëÇü°ú õ½Ä°ú COPDÀÇ ¼û°áÀ» Á¶ÀýÇϰí õ½Ä¿¡¼­ ºÎ½Å ÇÇÁú ½ºÅ×·ÎÀÌµå ¾à¹°ÀÇ È¿°ú¸¦ Áõ°¡Çϱâ À§ÇØ Á¤±âÀûÀ¸·Î »ç¿ëµÇ´Â Àå½Ã°£ ÀÛ¿ë À¯ÇüÀÌ ÀÖ½À´Ï´Ù. Ç×Äݸ°Á¦(Ç×¹«½ºÄ«¸°Á¦¶ó°íµµ ÇÔ)´Â ÁÖ·Î COPDÀÇ Ä¡·á¿¡ »ç¿ëµÇÁö¸¸ ÀϺδ õ½Ä¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Ç×Äݸ°Á¦´Â Äݸ°¼º ½Å°æÀ» Â÷´ÜÇÏ¿© ±âµµ¸¦ ³ÐÈü´Ï´Ù. ±â°üÁö È®ÀåÁ¦ÀÇ ºÎÀÛ¿ëÀº ƯÁ¤ ¾à¹°¿¡ µû¶ó ´Ù¸¨´Ï´Ù. ±â°üÁö È®ÀåÁ¦ÀÇ ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ƯÈ÷ ¼Õ ¶³¸², µÎÅë, ±ÙÀ° °æ·Ã, ¸Þ½º²¨¿ò, ±¸Åä, ¼³»ç µîÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº È£Èí±â Áúȯ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡, µµ½Ã,³óÃÌ ½Ö¹æ¿¡¼­ÀÇ È¯°æ ¿À¿° ·¹º§ÀÇ »ó½Â, õ½ÄÀ̳ª COPDÀÇ ÀûÀýÇÑ °ü¸®¿¡ °üÇÑ ÀÇ½Ä Áõ°¡ µîÀÇ ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª ´ëü Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º, ±â°üÁö È®ÀåÁ¦ÀÇ Àå±â°£ »ç¿ë°ú °ü·ÃµÈ ºÎÀÛ¿ë, ºí·Ï¹ö½ºÅÍ ¾à¹°ÀÇ Æ¯Çã ºÎÁ· µîÀÌ ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù. 2Á¾ ÀÌ»óÀÇ ¾à¹°À» µ¿½Ã¿¡ Åõ¿©ÇÒ ¼ö ÀÖ´Â º´¿ë ¿ä¹ýÀÇ °³Ã´Àº ÀÌ ½ÃÀåÀÇ ±â¾÷¿¡°Ô »õ·Î¿î ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ È£Èí±â Áõ»óÀ» ´õ Àß °ü¸®Çϱâ À§ÇÑ ¿¹¹æÀû ÈíÀÔ ¿ä¹ýÀÌ º¸´Ù Á߽õǰí ÇâÈÄ ¼ö¿ä¸¦ °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­´Â ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí 2023³âÀ» ±âÁØÀ¸·Î ÇÑ ¿¹Ãø±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)%À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã¿Í ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀº GSK plc., AstraZeneca, Mylan NV, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd. ., Sunovion Pharmaceuticals Inc., Sanofi, Innoviva µîÀÌ ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ±â°üÁö È®ÀåÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ±â°üÁöÈ®ÀåÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • Á¦Ç° ½ÂÀÎ Áõ°¡
    • ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ
    • °è¹ß Ä·ÆäÀÎ °­È­
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ½ÃÀå µ¿Çâ
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ¿ªÇÐ
  • Ä¡·á ¾Ë°í¸®Áò(ȯÀÚ ¿©Á¤)
  • Ä¡·á ¿É¼Ç ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ ½Å±Ô ÅõÀÚ
  • °¡°Ý ºÐ¼®
  • Áúº´ °è¹ß ÇÁ·Î±×·¥
  • Ä¡·áÀÇ ¾ÈÀü¼º°ú È¿´ÉÀÇ ºÐ¼®
  • ÇÕº´, Àμö ¹× Çù¾÷

Á¦4Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) À¯ÇàÀÇ ¿µÇâ

  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°(2019³â-2031³â)

  • º£Å¸ ¾Æµå·¹³¯¸° Àۿ뼺 ±â°üÁö È®ÀåÁ¦
  • Å©»êƾ À¯µµÃ¼
  • Ç×Äݸ° Àۿ뼺 ±â°üÁö È®ÀåÁ¦

Á¦6Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°(2019³â-2031³â)

  • °æ±¸
  • ºñ°­(ÈíÀÔ)
  • ÁÖ»ç

Á¦7Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå : ÀûÀÀÁõº°(2019³â-2031³â)

  • õ½Ä
  • ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)
  • ±âŸ(¸¸¼º ±â°üÁö¿° µî)

Á¦8Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå : À¯Åë ä³Îº°(2019³â-2031³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°è ±â°üÁö È®ÀåÁ¦ ½ÃÀå : Áö¿ªº°(2019³â-2031³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • GSK plc.
    • Mylan NV
    • Mylan NV
    • Merck &Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

Á¦11Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
BJH 24.04.25

The global bronchodilators market was valued US$ 22.85 Bn in 2023 and is expected to reach US$ 30.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 22.85 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.60% 2030/2031 Value Projection: US$ 30.44 Bn
Figure 1. Global Bronchodilators Market Share (%), By Region, 2023
Global Bronchodilators Market - IMG1

Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.

Market Dynamics:

The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.

Key features of the study:

  • This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market

Detailed Segmentation:

  • Global Bronchodilators Market, By Drug Class
    • Beta-adrenergic Bronchodilators
    • Xanthine Derivatives
    • Anticholinergic Bronchodilators
  • Global Bronchodilators Market, By Route of Administration
    • Oral
    • Nasal (inhalable)
    • Injectable
  • Global Bronchodilators Market, By Indication
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Others (Chronic bronchitis, etc.)
  • Global Bronchodilators Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bronchodilators Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Top Companies in the Global Bronchodilators Market:
    • GSK plc.
    • AbbVie Inc.
    • AstraZeneca
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Product Approval
    • Stringent Regulatory Environment
    • Increasing Awareness Campaigns
  • Key Highlights
  • Regulatory Scenario
  • Market Trends
  • Pipeline Analysis
  • Product Launch/Approval
  • PEST Analysis
  • PORTER's Analysis
  • Epidemiology
  • Treatment Algorithm (Patient Journey)
  • Treatment Option Analysis
  • New Investments by Major Market Players
  • Pricing Analysis
  • Disease Awareness Programs
  • Treatment Safety and Efficacy Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Bronchodilators Market, By Drug Class, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Beta-adrenergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Xanthine Derivatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Anticholinergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Bronchodilators Market, By Route of Administration, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Nasal (inhalable)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Bronchodilators Market, By Indication, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (Chronic bronchitis, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Bronchodilators Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 201s9-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

9. Global Bronchodilators Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Country, 2020 -2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
    • GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦